KRYS
Krystal Biotech, Inc.
NASDAQ · Healthcare · Biotechnology · US
$358.24
−3.56%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 440.5M | 389.1M | 290.5M | 50.7M | — |
| Cost of Revenue | 29.3M | 28.8M | 20.1M | 3.1M | — |
| Gross Profit | 411.1M | 360.4M | 270.5M | 47.6M | — |
| Operating Expenses | |||||
| R&D Expense | 59.2M | 58.0M | 53.6M | 46.4M | 42.5M |
| SG&A Expense | 159.7M | 146.7M | 113.7M | 98.4M | 77.7M |
| General & Admin Expense | 41.0M | — | — | — | 77.7M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (5.7M) | (5.7M) | 37.5M | 12.5M | 25.0M |
| Total Operating Expenses | 213.2M | 199.1M | 204.8M | 157.3M | 145.2M |
| Cost and Expenses | 242.6M | 227.8M | 224.8M | 160.4M | 145.2M |
| Operating Income (EBIT) | 197.9M | 161.3M | 65.7M | (109.7M) | (145.2M) |
| Non-Operating | |||||
| Interest Income | 7.9M | 28.2M | 29.7M | 22.6M | 5.2M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 7.9M | 28.2M | 29.7M | 22.6M | 5.2M |
| Other Non-Op Income/Expense | 28.7M | 28.2M | 29.7M | 122.6M | 5.2M |
| Non-Operating Income (excl Interest) | (15.4M) | (28.2M) | (37.5M) | (12.5M) | (25.0M) |
| EBT (Pre-Tax Income) | 226.6M | 189.5M | 95.4M | 12.9M | (140.0M) |
| Income Tax Expense | (14.8M) | (15.4M) | 6.2M | 2.0M | — |
| Bottom Line | |||||
| Net Income | 241.5M | 204.8M | 89.2M | 10.9M | (140.0M) |
| Earnings from Cont. Ops | 241.5M | 204.8M | 89.2M | 10.9M | (140.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 241.5M | 204.8M | 89.2M | 10.9M | (140.0M) |
| Per Share | |||||
| Basic EPS | $8.27 | $7.08 | $3.12 | $0.40 | ($5.49) |
| Diluted EPS | $7.98 | $6.84 | $3.00 | $0.39 | ($5.49) |
| Revenue Per Share | $14.92 | $13.44 | $10.16 | $1.87 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 29.5M | 28.9M | 28.6M | 27.2M | 25.5M |
| Diluted Shares Outstanding | 30.7M | 30.0M | 29.7M | 27.8M | 25.5M |
| Profitability Metrics | |||||
| EBITDA | 218.4M | 196.0M | 109.9M | (91.3M) | (116.8M) |
| D&A | 5.1M | 6.6M | 6.7M | 5.9M | 3.4M |
| EBIT | 213.3M | 189.5M | 103.2M | (97.2M) | (120.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026